Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-06-29

Clinical Trial Update: Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating avelumab with hypofractionated radiation therapy in IDH-mutant glioblastoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avelumab (avelumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2022-06-29